ClearTrial Industry Thought Leadership Spotlighted at DIA 23rd Annual EuroMeeting

Presentation topics showcase range and depth of ClearTrial clinical trial operations domain expertise

CHICAGO--(BUSINESS WIRE)-- ClearTrial (http://www.cleartrial.com), the leading provider of software for the planning, forecasting, and tracking of clinical project and financial performance, today announced that Melinda Davis, Director, Clinical Services at ClearTrial, will present two key topics at the DIA 23rd Annual EuroMeeting in Geneva, Switzerland. The EuroMeeting is a centerpiece event for professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, medical devices, and related products, attracting more than 3,000 industry professionals from over 50 countries.

Davis has been selected to give the following presentations:

“Reducing Clinical Trial Costs While Maintaining Study Achievability: Case Studies”
Tuesday, March 29, 2011, 11:00-12:30

Drawing on actual case studies, this presentation will examine areas which greatly impact study costs and are often prone to inefficiencies, such as monitoring, site location, and timelines for patient enrollment. Davis will then identify practical steps that leading biopharmaceutical companies are taking to reduce costs and make studies more efficient – without affecting their operational integrity.

“Effective Planning of Medical Device vs. Drug Clinical Studies: Key Considerations"
Wednesday, March 30, 2011, 09:00-10:30

Planning for clinical trials of medical devices poses additional and unique challenges when compared with planning clinical studies of drugs. In her presentation, Davis will examine key differences between medical device and drug studies, and how they affect planning from an operational perspective.

"One of the pillars of ClearTrial's success and of our software's high satisfaction level among our customers is the extensive clinical domain expertise we offer," noted Andrew Grygiel, Vice President of Marketing and Product Management for ClearTrial. "Melinda Davis is just one member of a global team of Clinical Services Directors who bring their expertise in clinical operations, finance, outsourcing, and project management to bear on both product evolution and top-notch customer service."

The DIA 23rd Annual EuroMeeting will be held at the Geneva Palexpo, 28-30 March 2011, in Geneva, Switzerland. For more information and to register, please visit http://www.diahome.org/diahome/FlagshipMeetings/home.aspx?meetingid=23313.

About ClearTrial®

ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, linking clinical planning, forecasting, and tracking of operational and financial performance in a single, integrated system. ClearTrial’s award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.



CONTACT:

Mike Lange
ClearTrial
+1 630.986.9800 x112
[email protected]

KEYWORDS:   United States  Europe  North America  Illinois  Switzerland

INDUSTRY KEYWORDS:   Technology  Software  Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.